HOME >> BIOLOGY >> NEWS
Pioneering experiments testing effects of greenhouse gases on crops

CHAMPAIGN, Ill. Portions of 40 acres of University of Illinois farmland this summer are sprouting soybeans grown in the presence of carbon dioxide levels forecast for the year 2050. Next summer, elevated levels of ozone will join the mix in a first-of-its-kind experiment called SoyFACE.

"When you consider the importance of the Midwest in terms of global food security, it is important to do this research here," said Stephen P. Long, a photosynthesis expert and the Robert Emerson Professor of Plant Biology at the UI. "Up to now, experiments related to global warming on many crops have been done in locations on the periphery of major food production areas."

Researchers want to know how soybeans may be affected, and what scientists might do to assure the integrity of yields and quality as the climate changes. By 2050, carbon dioxide levels are expected to be about 1.5 times greater than the current 370 parts per million, while daytime ozone levels during the growing season could peak on average at 80 parts per billion (now 60 parts per billion).

SoyFACE (Free Air gas Concentration Enrichment) is the first test of crop growth in the presence of both increased carbon dioxide and ozone. Five UI departments, the USDA-ARS and Illinois State Water Survey, as well as researchers from four other nations and two other U.S. universities are participating this summer.

Four control and four experimental 70-foot-diameter rings currently surround 24 varieties of soybeans. The experimental rings have ABS plastic pipes that deliver at crop level a precisely regulated flow of carbon dioxide, based on wind speed and direction, pumped from a 50-ton solar-powered tank.

Next summer, soybeans will grow on an adjacent 40 acres dotted with 24 of the octagon-shaped rings. Four rings will pump carbon dioxide, four will provide just ozone and four will provide ozone and carbon dioxide. Natural conditions will exist in an equal number of control rings for each test
'"/>

Contact: Jim Barlow
b-james3@uiuc.edu
217-333-5802
University of Illinois at Urbana-Champaign
2-Jul-2001


Page: 1 2

Related biology news :

1. Pioneering AIDS researcher to speak at UH
2. Pioneering discoveries, pursuing new knowledge, fostering partnerships
3. Pioneering flu researcher wins major Imperial scientific award
4. Pioneering study compares 13 vertebrate genomes
5. UFS Mcknight Brain Institute researchers: Pioneering spinal cord procedure appears safe
6. Pioneering evolutionist Ledyard Stebbins dies at age 94
7. Pioneering Research Could Lead To Treatment
8. Sandia experiments may reduce possibility of future water wars
9. APS recognizes Intel high school finalists for experiments in physiology
10. BioScience seeks nominations of beauteous experiments
11. ALife experiments show how complex functions can evolve

Post Your Comments:
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/17/2014)... 17, 2014 Tigercat Pharma, Inc. today ... evaluating the investigational oral NK-1 receptor antagonist VPD-737 ... chronic itch who are unresponsive or inadequately responsive ... steroids and antihistamines. The primary ... Scale (VAS) itch score from baseline, comparing drug ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
Cached News: